Jason Amello insider trades: Candel Therapeutics (CADL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jason reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 9, 2022 | CADL | ↑ Buy | 5,568 | $1.80 | $10K | Direct | Dec 12, 2022 (3d) |
| Feb 28, 2020 | AKBA | ↓ Sell | 6,976 | $8.70 | $61K | Direct | Mar 2, 2020 (3d) |
| Nov 26, 2014 | AKBA | ↑ Buy | 1,000 | $13.22 | $13K | Direct | Dec 1, 2014 (5d) |
| Mar 25, 2014 | AKBA | ↑ Buy | 4,000 | $17.00 | $68K | Direct | Mar 27, 2014 (2d) |
| Aug 31, 2010 | GENZ | ↓ Sell | 6,640 | $70.30 | $467K | Direct | Sep 2, 2010 (2d) |
| May 25, 2010 | GENZ | ↓ Sell | 533 | $45.62 | $24K | Direct | May 26, 2010 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CADL insiders
Open-market trades in the last 12 months
About Jason Amello's insider trades
Jason Amello is Chief Financial Officer at Candel Therapeutics (CADL). Since May 25, 2010, Jason has reported 3 open-market purchases worth $91K and 3 sales worth $552K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (25 filings), shares withheld for taxes (3 filings), option exercises (3 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CADL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.